Page last updated: 2024-12-06
cetaben
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 47263 |
| CHEMBL ID | 31907 |
| SCHEMBL ID | 2112078 |
| MeSH ID | M0069579 |
Synonyms (36)
| Synonym |
|---|
| benzoic acid, 4-(hexadecylamino)- |
| cetabeno [inn-spanish] |
| cetaben [inn] |
| 4-(n-hexadecylamino)benzoic acid |
| brn 2748166 |
| cetaben , |
| cetabenum [inn-latin] |
| 4-(hexadecylamino)benzoic acid |
| p-(hexadecylamino)benzoate |
| CHEMBL31907 |
| cetabenum |
| cetabeno |
| unii-dtl5w0113x |
| dtl5w0113x , |
| 55986-43-1 |
| FT-0603002 |
| QXWKHSSBFQDQPR-UHFFFAOYSA-N |
| 4-(n-hexadecylamino)-benzoic acid |
| p-hexadecylaminobenzoic acid |
| 4-(hexadecylamino)-benzoic acid |
| 4(hexadecylamino)benzoic acid |
| 4-n-hexadecylaminobenzoic acid |
| NCGC00261985-01 |
| SCHEMBL2112078 |
| HMS3650E11 |
| DTXSID70204558 |
| J-520012 |
| SR-01000944982-1 |
| sr-01000944982 |
| AKOS032947282 |
| HY-119964 |
| CS-0078843 |
| SR-01000944982-2 |
| Q27276596 |
| hexadecylamino-p-amino benzoic acid |
| MS-25733 |
Research Excerpts
Treatment
Cetaben treatment correlated with a fragmentation and/or condensation of Golgi cisternae and the appearance of large electron-lucent vesicles. HepG2 cells were treated with the drug.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Cetaben treatment correlated with a fragmentation and/or condensation of Golgi cisternae and the appearance of large electron-lucent vesicles." | ( The hypolipidemic compound cetaben induces changes in Golgi morphology and vesicle movement. Kovacs, WJ; Schrader, M; Stangl, H; Walter, I, 2004) | 1.34 |
| "Cetaben treatment of HepG2 cells caused disintegration of Golgi regions and augmented mitochondrial matrix." | ( Cetaben-induced changes on the morphology and peroxisomal enzymes in MH1C1 rat hepatoma cells and HepG2 human hepatoblastoma cells. Kovacs, W; Stangl, H; Walter, I, 2001) | 2.47 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " The data obtained in the dose-response study of cetaben revealed a significant rise in the activities of peroxisomal enzymes in both the liver and kidney at doses of 50-100 mg/kg body wt administered over 10 days, but the maximal effect was observed at 250 mg/kg." | ( Cetaben and fibrates both influence the activities of peroxisomal enzymes in different ways. Chandoga, J; Hampl, L; Hocman, G; Rojeková, I, 1994) | 1.99 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (23)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID175081 | In vivo Triglyceride lowering activity at dose as 0.01 % of the diet | 1983 | Journal of medicinal chemistry, Oct, Volume: 26, Issue:10 | Potential antiatherosclerotic agents. 2. (Aralkylamino)- and (alkylamino) benzoic acid analogues of cetaben. |
| AID175057 | In vivo Sterol lowering activity at dose as 0.03 % of the diet | 1983 | Journal of medicinal chemistry, Oct, Volume: 26, Issue:10 | Potential antiatherosclerotic agents. 2. (Aralkylamino)- and (alkylamino) benzoic acid analogues of cetaben. |
| AID175058 | In vivo sterol lowering activity, dosed as 0.03 % of the diet | 1983 | Journal of medicinal chemistry, Oct, Volume: 26, Issue:10 | Potential antiatherosclerotic agents. 4. [(Functionalized-alkyl)amino]benzoic acid analogues of cetaben. |
| AID31507 | In vitro inhibitory activity against acyl coenzyme A:cholesterol acyltransferase (ACAT) | 1983 | Journal of medicinal chemistry, Oct, Volume: 26, Issue:10 | Potential antiatherosclerotic agents. 2. (Aralkylamino)- and (alkylamino) benzoic acid analogues of cetaben. |
| AID174922 | In vivo Sterol lowering activity at dose as 0.01% of the diet | 1983 | Journal of medicinal chemistry, Oct, Volume: 26, Issue:10 | Potential antiatherosclerotic agents. 4. [(Functionalized-alkyl)amino]benzoic acid analogues of cetaben. |
| AID31508 | In vitro inhibition of acyl coenzyme A:cholesterol acyltransferase | 1983 | Journal of medicinal chemistry, Oct, Volume: 26, Issue:10 | Potential antiatherosclerotic agents. 3. Substituted benzoic and non benzoic acid analogues of cetaben. |
| AID175250 | In vivo Triglyceride lowering activity at a dose of 0.10 % of the diet | 1983 | Journal of medicinal chemistry, Oct, Volume: 26, Issue:10 | Potential antiatherosclerotic agents. 4. [(Functionalized-alkyl)amino]benzoic acid analogues of cetaben. |
| AID175249 | In vivo triglyceride lowering activity dosed at 0.10 % of the diet | 1983 | Journal of medicinal chemistry, Oct, Volume: 26, Issue:10 | Potential antiatherosclerotic agents. 2. (Aralkylamino)- and (alkylamino) benzoic acid analogues of cetaben. |
| AID175061 | In vivo sterol lowering activity when dosed as 0.03 % of the diet | 1983 | Journal of medicinal chemistry, Oct, Volume: 26, Issue:10 | Potential antiatherosclerotic agents. 3. Substituted benzoic and non benzoic acid analogues of cetaben. |
| AID175071 | In vivo sterol lowering activity at dose of 0.10 % of the diet | 1983 | Journal of medicinal chemistry, Oct, Volume: 26, Issue:10 | Potential antiatherosclerotic agents. 4. [(Functionalized-alkyl)amino]benzoic acid analogues of cetaben. |
| AID175070 | In vivo sterol lowering activity dosed at 0.10 % of the diet | 1983 | Journal of medicinal chemistry, Oct, Volume: 26, Issue:10 | Potential antiatherosclerotic agents. 2. (Aralkylamino)- and (alkylamino) benzoic acid analogues of cetaben. |
| AID175238 | In vivo triglyceride lowering activity when dosed at 0.03 % of the diet | 1983 | Journal of medicinal chemistry, Oct, Volume: 26, Issue:10 | Potential antiatherosclerotic agents. 3. Substituted benzoic and non benzoic acid analogues of cetaben. |
| AID175045 | In vivo sterol lowering activity when dosed as 0.01 % of the diet | 1983 | Journal of medicinal chemistry, Oct, Volume: 26, Issue:10 | Potential antiatherosclerotic agents. 3. Substituted benzoic and non benzoic acid analogues of cetaben. |
| AID175102 | In vivo Triglyceride lowering activity at dose as 0.03 % of the diet | 1983 | Journal of medicinal chemistry, Oct, Volume: 26, Issue:10 | Potential antiatherosclerotic agents. 4. [(Functionalized-alkyl)amino]benzoic acid analogues of cetaben. |
| AID175253 | In vivo triglyceride lowering activity dosed at 0.10 % of the diet. | 1983 | Journal of medicinal chemistry, Oct, Volume: 26, Issue:10 | Potential antiatherosclerotic agents. 3. Substituted benzoic and non benzoic acid analogues of cetaben. |
| AID31509 | In vitro inhibitory activity against acyl coenzyme A:cholesterol acyltransferase | 1983 | Journal of medicinal chemistry, Oct, Volume: 26, Issue:10 | Potential antiatherosclerotic agents. 4. [(Functionalized-alkyl)amino]benzoic acid analogues of cetaben. |
| AID174921 | In vivo Sterol lowering activity at dose as 0.01 % of the diet | 1983 | Journal of medicinal chemistry, Oct, Volume: 26, Issue:10 | Potential antiatherosclerotic agents. 2. (Aralkylamino)- and (alkylamino) benzoic acid analogues of cetaben. |
| AID175082 | In vivo Triglyceride lowering activity at dose as 0.01 % of the diet | 1983 | Journal of medicinal chemistry, Oct, Volume: 26, Issue:10 | Potential antiatherosclerotic agents. 4. [(Functionalized-alkyl)amino]benzoic acid analogues of cetaben. |
| AID175101 | In vivo triglyceride lowering activity, dosed at 0.03 % of the diet | 1983 | Journal of medicinal chemistry, Oct, Volume: 26, Issue:10 | Potential antiatherosclerotic agents. 2. (Aralkylamino)- and (alkylamino) benzoic acid analogues of cetaben. |
| AID645239 | Antiviral activity against Rotavirus SA11 in MA104 cells assessed as inhibition of viral replication after 24 hrs by immunofluorescent assay and Western blotting analysis | 2012 | European journal of medicinal chemistry, Apr, Volume: 50 | Novel triacsin C analogs as potential antivirals against rotavirus infections. |
| AID175074 | In vivo sterol lowering activity at dose of 0.10 % of the diet | 1983 | Journal of medicinal chemistry, Oct, Volume: 26, Issue:10 | Potential antiatherosclerotic agents. 3. Substituted benzoic and non benzoic acid analogues of cetaben. |
| AID645241 | Cytotoxicity against monkey MA104 cells after 24 hrs | 2012 | European journal of medicinal chemistry, Apr, Volume: 50 | Novel triacsin C analogs as potential antivirals against rotavirus infections. |
| AID175085 | In vivo triglyceride lowering activity when dosed as 0.01 % of the diet | 1983 | Journal of medicinal chemistry, Oct, Volume: 26, Issue:10 | Potential antiatherosclerotic agents. 3. Substituted benzoic and non benzoic acid analogues of cetaben. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (18)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 9 (50.00) | 18.7374 |
| 1990's | 5 (27.78) | 18.2507 |
| 2000's | 3 (16.67) | 29.6817 |
| 2010's | 1 (5.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 40.12
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (40.12) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (5.56%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 17 (94.44%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||